CONCLUSION:
MIS-N is no longer a hypothesis, but an actual disease entity with
multiple reports available in literature. This disease is ever-evolving
with widening scope of symptomatology. Thromboembolic complications
secondary to inflammatory response after SARS-CoV2 exposure should be
considered in infants and children. It is essential for the
neonatologists to consider the possibility of MIS-N in neonates with
in-utero exposure for early diagnosis and management as well as share
the data for better understanding of the disease and framing the best
treatment practices. Diagnostic criteria and management strategies for
MIS-N as well as thromboembolism in MIS-N should be developed, distinct
from those currently available for children.